Bitget App
Trade smarter
Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Bitget-RWA2025/10/24 12:32
By:Bitget-RWA

- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.

Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an

. The ChonDRAgon clinical trial, which compared ozekibart as a standalone treatment to placebo, achieved its main goal by showing a statistically significant 52% decrease in the risk of disease progression or death relative to the control group. Patients administered ozekibart experienced a median progression-free survival (PFS) of 5.52 months, more than twice the 2.66 months seen in those receiving placebo. Additionally, the drug achieved a disease control rate of 54% compared to 27.5% for placebo, with consistent positive outcomes across all predefined subgroups, according to .

Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in

.

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety image 0

In addition to chondrosarcoma,

shared encouraging interim results from expansion cohorts evaluating ozekibart in combination regimens for colorectal cancer and Ewing sarcoma. Among heavily pretreated colorectal cancer patients, the combination of ozekibart with FOLFIRI chemotherapy resulted in a 23% overall response rate and a 92% disease control rate. For Ewing sarcoma, pairing ozekibart with irinotecan and temozolomide yielded a 64% overall response rate and a 92% disease control rate, as reported by Investing.com. These outcomes indicate that the therapy may have broader potential in oncology.

The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.

The market responded strongly to the announcement, with

shares climbing from $28.36 on October 23 to $46.30 in pre-market trading the next day—a 63.26% increase, according to Tokenist. This jump followed a 10% drop in the previous session, highlighting the volatility typical of biotech equities. Trading volume surged to 1.15 million shares, far above the average of 151,435, per Tokenist. Retail investors on platforms such as Stocktwits became "extremely bullish," with message activity rising by 985% in 24 hours, as tracked by .

Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to

. However, the company posted a net loss of $28.65 million in the latest quarter, mainly due to substantial research and development spending, as reported by . Despite these losses, analysts see ozekibart as a potential revenue driver if it gains regulatory approval.

INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

x402’s 10,780% Spike Marks a New Era of AI-Powered Payment Transformation

- Coinbase's x402 protocol surged 10,780% in transactions post-PING launch, enabling AI-native payments via HTTP 402. - PING token drove $140k+ weekly volume, with Binance's integration amplifying speculation and market cap growth. - a16z forecasts $30T in AI-driven transactions by 2030, positioning x402 as foundational for autonomous commerce. - Volatility and regulatory scrutiny highlight risks in tokenization's rapid adoption despite protocol's technical promise.

Bitget-RWA2025/10/26 04:56
x402’s 10,780% Spike Marks a New Era of AI-Powered Payment Transformation

Patience Rewarded: Polymarket’s Postponed Token Sparks $15B Jump in Valuation

- Polymarket plans to launch a native token and airdrop after reentering the U.S. market via a $112M QCX acquisition. - The token prioritizes "real utility" and fair distribution, with 5-10% allocated to user-based airdrop rewards. - Institutional backing including ICE's $2B investment has driven Polymarket's valuation to $12-15B, up from $1B in June. - Strategic U.S. expansion includes NHL partnerships and DraftKings integration, positioning it as a crypto-traditional finance bridge.

Bitget-RWA2025/10/26 04:56
Patience Rewarded: Polymarket’s Postponed Token Sparks $15B Jump in Valuation

China's Stablecoin Restrictions: Authorities Balance Technological Progress with Economic Security

- China's regulators halt mainland firms' stablecoin projects in Hong Kong to address financial stability risks. - Global stablecoin usage expands beyond crypto trading, but high fees persist, with USDT dominating the market. - Kyrgyzstan launches KGST stablecoin and plans a CBDC to boost international settlements and digital currency adoption. - Experts note China's regulatory actions aim to balance innovation with risk management, maintaining competitiveness against the U.S.

Bitget-RWA2025/10/26 04:40

AI Agents Liberated from Subscription Fees: x402-Powered aixbt Jumps by 32.8%

- Aixbt token surged 32.8% after integrating with x402, a Coinbase-backed protocol enabling AI agents to autonomously transact using stablecoins without subscriptions or KYC. - The update grants access to real-time data on Web3 trends and metaverse projects, aligning with x402's vision for low-cost, decentralized AI-driven interactions. - Despite ecosystem fragmentation and competition among 15+ facilitators, x402's institutional backing from Google and Visa highlights growing confidence in monetizing AI s

Bitget-RWA2025/10/26 04:40
AI Agents Liberated from Subscription Fees: x402-Powered aixbt Jumps by 32.8%